Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science.
Compston
J
J
Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK. jec1001@cam.ac.uk
Reid
D M
DM
Boisdron
J
J
Brandi
M-L
ML
Burlet
N
N
Cahall
D
D
Delmas
P D
PD
Dere
W
W
Devogelaer
J-P
JP
Fitzpatrick
L A
LA
Flamion
B
B
Goel
N
N
Korte
S
S
Laslop
A
A
Mitlak
B
B
Ormarsdottir
S
S
Ringe
J
J
Rizzoli
R
R
Tsouderos
Y
Y
Van Staa
T
T
Reginster
J-Y
JY
D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000379:methods*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D012107:Research Design; D012737:Sex Factors
D050071:Bone Density Conservation Agents; D005938:Glucocorticoids